Table 2.
Cross-reactivity analysis.
| Cross Reactivity Studies |
sBCMA Concentration of 70.0 ng/mL |
||
|---|---|---|---|
| Drug Name | Drug Concentration (% of total solution) | Percent Cross -Reactivity | Percent Recovery |
| Daratumumab | 5% | 3% | 103% |
| 10% | −4% | 96% | |
| Isatuximab | 5% | 2% | 101% |
| 10% | −4% | 97% | |
| Talquetamab | 2% | 1% | 101% |
| 5% | 4% | 105% | |
| 8% | −1% | 103% | |
| 10% | 0.4 | 105% | |
| Belantamab | 1% | −1875% | 5% |
| 5% | −2477% | 4% | |
| 10% | −2168% | 5% | |
| AMG 701 | 2% | −474% | 18% |
| 5% | −923% | 10% | |
| 8% | −966% | 10% | |
| 10% | −998% | 10% | |